OXT and obesity due to melanocortin 4 receptor deficiency: Studies have highlighted the anorexigenic properties of OXT and its role in modulating caloric intake and energy homeostasis [1,2,3,4,5,6,7,8], with recent trials investigating the use of intranasal OXT as a potential therapeutic intervention in the management of obesity [6,7,9,10,11].